Most of the market went up on Tuesday. HCA Healthcare went the other way, falling about 7% in its fifth straight losing session while the S&P 500 closed higher on cooler inflation and a chip rally. The reason was a fresh warning that a policy change investors have watched for a year is now biting harder than the company expected.
HCA told the market it now sees a pretax income drag of $1 billion to $1.2 billion this year from the expiration of enhanced Affordable Care Act subsidies. Its earlier estimate was $600 million to $900 million. The company trimmed full-year adjusted earnings guidance to a range of $28.70 to $30.50 per share, down from $29.10 to $31.50, and narrowed its revenue outlook to $77 billion to $79.5 billion.
What actually changed
The enhanced ACA subsidies expired at the end of 2025. Those credits made exchange coverage cheap, and cheap coverage sent paying patients into hospitals. With the credits gone, premiums jumped and enrollment is falling. HCA now expects its ACA exchange volumes to drop 15% to 20% this year, and it says 80% to 85% of those lost patients end up uninsured rather than switching to another plan.
That is the part that hurts. An uninsured patient still shows up in the emergency room, but the bill often turns into bad debt instead of revenue. HCA already absorbed roughly $150 million of this in the first quarter, with exchange admissions down about 15% from a year earlier. The larger guidance cut says the trend got worse, not better.
Why the whole sector fell
HCA is the biggest for-profit hospital chain in the country, so its read on the exchange population is the sector's read. Pure-play peers Universal Health Services and Tenet Healthcare face the same subsidy squeeze, since both lean on the same exchange enrollees for admissions and surgical volume.
The damage spread to the companies that sell into hospitals, too. Intuitive Surgical and Abbott slipped on the read-through, because fewer insured patients means fewer elective procedures and fewer devices sold. HCA's own numbers back that up: inpatient surgeries fell 2.3% and outpatient surgeries fell 3.4%, the kind of high-margin volume that pays for a hospital's fixed costs.
The question for investors
Here is the tension. HCA trades at roughly 12 times earnings, near the low end of its own history and well below the broad market. The stock is down more than 30% from its 52-week high, and it still throws off a modest dividend while the company buys back large amounts of stock every year. On paper, that is a value setup.
The counterweight is that nobody knows where the enrollment drop bottoms out. If Congress restores the subsidies, the volume comes back and the stock looks cheap. If it does not, HCA management says its own cost cuts can hold the net hit to between $200 million and $500 million, but the bad-debt drag keeps building. The market spent Tuesday deciding it does not want to guess, and it sold first.
What to watch next
HCA reports full second-quarter results later this month, and the language on payer mix and bad debt will matter more than the headline earnings number. Watch whether Universal Health and Tenet echo the same guidance pressure when they report, and whether any subsidy fix gains traction in Washington. Until one of those shifts, hospital stocks are pricing a coverage cliff with no clear floor.
